Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical study
- 15 June 2010
- journal article
- Published by Springer Science and Business Media LLC in Virchows Archiv
- Vol. 457 (1), 27-34
- https://doi.org/10.1007/s00428-010-0939-z
Abstract
This study was aimed at determining whether high-grade endometrioid carcinomas (grade 3 International Federation of Gynecology and Obstetrics) might overlap, at least partially, non-endometrioid carcinomas (type II). To this end, a panel of clinical–pathological and immunohistochemical parameters was evaluated in three different populations: low-grade endometrioid carcinomas (LGECs; n = 57), high-grade endometrioid carcinomas (HGECs; n = 26), and non-endometrioid carcinomas (NECs; n = 30). Besides morphological appearance, HGECs appeared similar to LGECs in p53 immunostaining profile; features different from LGECs included a higher local aggressiveness, a higher invasion of lymph-vascular spaces, a lower expression of ERα and PR, and a higher proliferative index. HGECs were similar to NECs for local aggressiveness, invasion rate of lymph-vascular spaces, lymph node metastasis incidence, and proliferative index. HGECs, however, showed a lower rate of extra-nodal metastases, a lower incidence of p53 overexpression, and a higher positivity for ERα and PR. In conclusion, results from this study show that HGECs exhibit overlapping morphological and immunohistochemical features of both type I and type II endometrial carcinomas. Further research is needed to clarify the clinical value of this observation.Keywords
This publication has 20 references indexed in Scilit:
- Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell typeJournal of Clinical Pathology, 2010
- Pharmacotherapy of endometrial cancerExpert Opinion on Pharmacotherapy, 2009
- Resistance to chemotherapy and hormone therapy in endometrial cancerEndocrine-Related Cancer, 2009
- Current Issues in the Management of Endometrial CancerMayo Clinic Proceedings, 2008
- Novel molecular profiles of endometrial cancer—new light through old windowsThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- Endometrial cancerThe Lancet, 2005
- Interpretation of p53 Immunoreactivity in Endometrial Carcinoma: Establishing a Clinically Relevant Cut-Off LevelInternational Journal of Gynecological Pathology, 2004
- Prognostic Significance of Angiogenesis and Ki-67, p53, and p21 Expression: A Population-Based Endometrial Carcinoma StudyJournal of Clinical Oncology, 1999
- Recent advances in the histopathology and molecular pathology of carcinoma of the endometriumHistopathology, 1998
- Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiationHuman Pathology, 1998